Financials · LYEL

Lyell Immunopharma Inc. (LYEL) financials

For the twelve months ended Sep 30, 2026, Lyell Immunopharma Inc. reported $15.0K of revenue and -$255.16M of net income.

Revenue, TTM
$15.0K
Revenue growth, YoY
-63.4%
Net income, TTM
-$255.16M
Net margin
-1701066.7%
Free cash flow, TTM
-$139.97M
EPS, diluted, TTM
-$12.38
Cash
$92.05M
P/S
29646.55
Market cap
$444.7M
Annual revenue$36.0K
FY2019FY2025
Annual net income-$274.45M
FY2019FY2025
Annual free cash flow-$150.80M
FY2019FY2025

LYEL revenue and earnings growth

LYEL revenueQ3 2026$3.0K

Quarter YoY
-80.0%
QoQ
-25.0%
FY YoY
-41.0%
5Y CAGR
-65.9%

LYEL revenue was $3.0K in fiscal Q3 2026 (ended Sep 30, 2026), down 80.0% from a year earlier and down 25.0% from the prior quarter. For the full fiscal 2025 it was $36.0K, down 41.0% from fiscal 2024. Compound annual growth was -65.9% over 5 years. It rose in 3 of the last 6 fiscal years.

LYEL net incomeQ3 2026-$45.53M

LYEL net income was -$45.53M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$38.85M a year earlier. For the full fiscal 2025 it was -$274.45M, compared with -$342.99M in fiscal 2024.

LYEL EPSQ3 2026-$1.86

LYEL diluted EPS was -$1.86 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$2.13 a year earlier. For the full fiscal 2025 it was -$16.06, compared with -$26.23 in fiscal 2024.

LYEL free cash flowQ3 2026-$34.63M

LYEL free cash flow was -$34.63M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$28.64M a year earlier. For the full fiscal 2025 it was -$150.80M, compared with -$162.86M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Revenue$36.0K$61.0K$130.0K$84.68M$10.65M$7.76M$657.0K
Research and development$158.68M$171.60M$182.94M$159.19M$138.69M$182.24M$63.59M
Selling, general and admin$45.13M$52.04M$66.98M$117.31M$89.06M$46.88M$39.15M
Operating income-$269.40M-$358.75M-$247.01M-$187.06M-$214.78M-$211.94M-$102.09M
Income tax$0------
Net income-$274.45M-$342.99M-$234.63M-$183.12M-$250.22M-$204.47M-$129.38M
EPS, basic-$16.06-$26.23-$18.70-$14.80-$36.80-$313.80-$480.80
EPS, diluted-$16.06-$26.23-$18.70-$14.80-$36.80-$313.80-$480.80
Diluted shares17.1M13.1M12.5M12.4M6.8M662,900271.45

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Cash and equivalents$60.18M$107.29M$145.65M$123.83M$294.29M$140.87M$98.47M
Short-term investments$187.04M$264.93M$400.58M$516.60M$320.97M$472.21M-
Current assets$260.94M$379.59M$554.69M$651.29M$626.29M$617.55M-
Total assets$340.05M$490.86M$750.03M$937.56M$1.13B$908.28M-
Current liabilities$49.41M$53.79M$34.52M$37.03M$46.74M$49.28M-
Total liabilities$91.85M$108.03M$95.08M$104.31M$197.62M$189.84M-
Shareholders' equity$248.20M$382.82M$654.95M$833.25M$929.79M-$292.53M-$111.11M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Operating cash flow-$150.02M-$162.39M-$163.69M-$169.56M-$126.25M-$160.87M$39.47M
Capital expenditures$780.0K$464.0K$2.69M$24.28M$65.50M$51.48M$16.05M
Free cash flow-$150.80M-$162.86M-$166.38M-$193.83M-$191.75M-$212.35M$23.43M
Investing cash flow$54.10M$122.42M$184.05M-$11.54M-$121.57M-$273.52M-$422.43M
Financing cash flow$50.41M$1.33M$1.74M$10.63M$401.24M$476.79M$351.16M
Share repurchases---$0$0$11.81M$185.0K
Stock-based compensation$41.83M$33.14M$47.08M$81.92M$62.20M$33.26M$15.73M
Depreciation and amortization$11.54M$19.63M$20.25M$18.02M$13.62M$4.29M$1.26M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Revenue growth, YoY-41.0%-53.1%-99.8%695.1%37.3%1080.5%-
Operating margin-748344.4%-588123.0%-190006.2%-220.9%-2016.7%-2732.6%-15538.7%
Net margin-762355.6%-562285.2%-180486.2%-216.2%-2349.5%-2636.3%-19692.1%
Free cash flow margin-418900.0%-266980.3%-127984.6%-228.9%-1800.5%-2737.9%3565.8%
Return on equity-110.6%-89.6%-35.8%-22.0%-26.9%--
Return on assets-80.7%-69.9%-31.3%-19.5%-22.2%-22.5%-
Current ratio5.287.0616.0717.5913.4012.53-

Source: XBRL data Lyell Immunopharma Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Aug 12, 2025.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

LYEL peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
LYEL$15.0K-63.4%-$255.16M-1701066.7%$444.7M
LLY$86.46B+45.5%$27.58B31.9%$1.30T
JNJ$99.33B+7.8%$16.09B16.2%$656.47B
ABBV$66.01B+10.7%$10.34B15.7%$505.56B
MRK$67.38B+4.9%$2.45B3.6%$339.66B
NVS$54.53B+8.4%$13.98B25.6%$296.16B
AZN$58.74B+8.6%$10.22B17.4%$277.21B
ABT$48.23B+10.0%$4.70B9.7%$180.95B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$174.57B

LYEL FAQ

8 questions
  • What is LYEL revenue?
    Lyell Immunopharma Inc. (LYEL) reported $15.0K of revenue for the twelve months ended Sep 30, 2026. That is down 63.4% from the year before. Revenue for fiscal 2025 was $36.0K.
  • Is LYEL profitable?
    No. Lyell Immunopharma Inc. reported a net loss of $255.16M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does LYEL have?
    Lyell Immunopharma Inc. reported $92.05M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is LYEL revenue growing?
    Lyell Immunopharma Inc.'s revenue changed -41.0% in fiscal 2025, to $36.0K. Its compound annual growth rate was -65.9% over 5 years.
  • What is LYEL free cash flow?
    Lyell Immunopharma Inc. generated -$139.97M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$139.25M less capital expenditures.
  • What is LYEL earnings per share?
    Diluted earnings per share were -$12.38 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did LYEL last report financial results?
    The latest statements here come from Lyell Immunopharma Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this LYEL financial data come from?
    Quantisnow builds these statements from the structured XBRL data Lyell Immunopharma Inc. files with the SEC. It is provided for information only and is not investment advice.